UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-1187261 (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-1187261 (State or other jurisdic ...

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Q4 2022 Earnings Conference Call March 8, 2023 8:00 AM ET Company Participants Louisa Stone - Manager, Investor Relations Scott Myers - President and Chief Executive Officer Kristian Humer - Chief Financial Officer Deepa Rajagopalan - Chief Product and Strategy Officer Todd James - Senior Vice President, Corporate Affairs and Investor Relations Conference Call Participants Gavin Clark-Gartner - Evercore ISI Laura Chico - Wedbush Securities Jason Butler - JMP Securit ...

%VIRIDIAN J.P. Morgan 41st Annual Healthcare Conference January 9, 2023 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "woul ...

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants John Jordan - Vice President of Investor Relations Jonathan Violin - President & Chief Executive Officer Barrett Katz - Chief Medical Officer Kristian Humer - Chief Financial Officer & Chief Business Officer Conference Call Participants Rami Katkhuda - LifeSci Capital Gavin Clark-Gartner - Evercore ISI Thomas Smith - SVB Securities Laura Chico - Wedbush Securities Kalpit Patel - B. Ri ...

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Q2 2022 Earnings Conference Call August 15, 2022 8:00 AM ET Company Participants John Jordan - VP of IR Jonathan Violin - President and CEO Barrett Katz - Chief Medical Officer, Raymond Douglas - Director of Thyroid Eye Disease Kristian Humer - CFO and Chief Business Officer Conference Call Participants Chris Howerton - Jefferies Thomas Smith - SVB Securities Gavin Clark-Gartner - Evercore ISI Rami Katkhuda - LifeSci Capital Laura Chico - Wedbush Securities Kalpit P ...

| --- | --- | |-----------------------------------------------------------------------------|-------| | | | | ENGINEERING MEDICINES | | | TO IMPROVE PATIENT CARE *VIRIDIAN VRDN-001 & VRDN-002 initial clinical data | | | August 15, 2022 | | Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, "anti ...

Viridian Therapeutics May 2022 %VIRIDIAN Cautionary note regarding forward-looking statements This presentation contains forward-looking statements relating to Viridian Therapeutics, Inc., including statements about our plans to obtain funding, develop and commercialize our therapeutic candidates, our planned clinical trials, the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates, the clinical utility of our therapeutic candidates and our intellectual proper ...

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants John Jordan - VP, Investor Relations and Corporate Communications Jonathan Violin - CEO, President & Director Kristian Humer - CFO, Chief Business Officer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Christopher Howerton - Jefferies Thomas Smith - SVB Leerink Laura Chico - Wedbush Securities Rami Katkhuda - LifeSci Capital Jason Butler - JMP Secu ...

Viridian Therapeutics April 2022 %VIRIDIAN Cautionary note regarding forward-looking statements This presentation contains forward-looking statements relating to Viridian Therapeutics, Inc., including statements about our plans to obtain funding, develop and commercialize our therapeutic candidates, our planned clinical trials, the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates, the clinical utility of our therapeutic candidates and our intellectual prop ...